

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sunho Biologics, Inc.

盛禾生物控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2898)

**CLARIFICATION ANNOUNCEMENT
FURTHER DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS
AND
CONTINUED SUSPENSION OF TRADING**

References are made to the announcements (the “**Announcements**”) published by the Company dated March 27, 2026, March 30, 2026, April 1, 2026 and April 21, 2026 in relation to the delay in publication of the 2025 Annual Results, postponement of Board Meeting and suspension of trading. Unless otherwise stated, capitalized terms shall have the same meanings as those defined in the Announcements.

FURTHER DELAY IN PUBLICATION OF THE 2025 ANNUAL RESULTS

The Company disclosed in the Announcement dated April 21, 2026 that, after taking into account the then situation, it was expected that the 2025 Annual Results would be published by April 30, 2026, subject to completion of all outstanding works of the 2025 Annual Audit.

The Company would like to clarify that, as of the date of this Announcement, the Auditor has not yet completed all outstanding works of the 2025 Annual Audit. As a result of the foregoing, the Company is unable to publish its 2025 Annual Results by April 30, 2026 as previously announced.

The Company has always been making its best efforts to complete the 2025 Annual Audit as soon as possible. Further announcements with respect to the status of 2025 Annual Audit and the publication of 2025 Annual Results will be made by the Company as and when appropriate.

DELAY IN DESPATCH OF 2025 ANNUAL REPORT

Pursuant to Rule 13.46(2)(a) of the Listing Rules, the Company is required to despatch its annual report for the year ended December 31, 2025 (the “**2025 Annual Report**”) no later than four months after the end of the financial year (i.e., on or before April 30, 2026). Due to the delay in the publication of the 2025 Annual Results, it is expected that there will be delay in the despatch of the 2025 Annual Report. Such delay will be inconsistent with Rule 13.46(2)(a) of the Listing Rules. The Company will publish further announcement(s) to inform its shareholders and potential investors of the despatch date of the 2025 Annual Report as and when appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on April 1, 2026 and will continue to be suspended pending the publication of the 2025 Annual Results by the Company.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, April 27, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; the non-executive Director is Mr. FAN Rongkui; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.